alanine has been researched along with Hepatitis B in 28 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It remains unknown whether tenofovir alafenamide (TAF) could replace tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV)." | 9.51 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. ( Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC, 2022) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 9.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes." | 9.27 | 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. ( Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT, 2018) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 9.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 8.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 8.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 8.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 8.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| " However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months." | 7.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 5.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "It remains unknown whether tenofovir alafenamide (TAF) could replace tenofovir disoproxil fumarate (TDF) in patients with drug-resistant hepatitis B virus (HBV)." | 5.51 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. ( Byun, KS; Choi, J; Gwak, GY; Kim, JH; Kim, YJ; Kwon, SY; Lee, HC; Lee, YS; Lim, YS; Yoo, BC, 2022) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 5.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| "The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B patients." | 5.41 | Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. ( Hwang, EG; Jung, EA; Kim, SG; Kim, YS; Yoo, JJ, 2023) |
| "Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF) through more efficient delivery of tenofovir to hepatocytes." | 5.27 | 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. ( Agarwal, K; Ahn, SH; Bae, H; Bhardwaj, N; Brunetto, M; Buti, M; Cathcart, AL; Çelen, MK; Chan, HLY; Chuang, WL; Flaherty, JF; Fung, S; Furusyo, N; Gaggar, A; Gane, EJ; Izumi, N; Janssen, HLA; Lau, AH; Lim, YS; Lin, L; Mani Subramanian, G; Marcellin, P; Pan, CQ; Seto, WK; Shalimar, D; Sharma, M; Suri, V; Trinh, H; Yoon, KT, 2018) |
| "Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B." | 5.22 | Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. ( Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S, 2016) |
| "Tenofovir (TFV) is the cornerstone of the treatment and prophylaxis of HIV infections." | 4.98 | Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. ( De Clercq, E, 2018) |
| "The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations." | 4.98 | Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. ( Asriel, B; Chan, L; Eaton, EF; Wyatt, CM, 2018) |
| "Switching to a tenofovir alafenamide (TAF)-containing regimen has been reported to be associated with body weight gain in human immunodeficiency virus-infected subjects." | 4.12 | Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide ( Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Nguyen, MH; Trinh, S; Yeh, ML; Yu, ML, 2022) |
| "Antenatal antiviral therapy (AVT) is effective in preventing mother-to-child transmission (MTCT) in chronic hepatitis B (CHB); tenofovir disoproxil fumarate (TDF) is the preferred agent." | 4.12 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection. ( Cottrell, M; Crane, H; Di Girolamo, J; Dumond, J; Gane, E; Kashuba, A; Kayes, T; Levy, MT; Lim, TH; Manandhar, S; Symonds, A, 2022) |
| "Although tenofovir alafenamide (TAF) and besifovir dipivoxil maleate (BSV) are potent antiviral agents in the treatment of chronic hepatitis B (CHB) infection, their renal safety profiles have not been previously compared." | 4.12 | Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B. ( Ahn, SH; Jung, CY; Kim, BS; Kim, HW; Kim, SU; Lee, HW; Lee, JI, 2022) |
| "Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV)." | 4.02 | Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. ( Chen, ZM; Cui, GL; Ji, F; Li, GM; Li, J; Li, W; Li, ZQ; Liang, HX; Liu, YM; Lv, J; Pan, YJ; Sun, CY; Wang, FS; Xu, JH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, GF, 2021) |
| " However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months." | 3.01 | Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. ( Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023) |
| " Tenofovir is an important component of management, but the associated risk of nephrotoxicity makes dosing a challenge in patients with impaired kidney function." | 1.72 | Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa. ( Barday, Z; Geragotellis, A; Naicker, V; Patel, S; Sanglay, L; Sonderup, M; Spearman, CW; Wearne, N, 2022) |
| "Antiviral agents for chronic hepatitis B (CHB) reduced the risk of hepatocellular carcinoma (HCC) development." | 1.62 | Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. ( Ahn, SH; Chon, HY; Kim, SU; Kim, YJ; Lee, JH; Sinn, DH; Yoon, JH, 2021) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 1.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 19 (67.86) | 2.80 |
| Authors | Studies |
|---|---|
| Korolowicz, KE | 1 |
| Suresh, M | 1 |
| Li, B | 1 |
| Huang, X | 1 |
| Yon, C | 1 |
| Kallakury, BV | 1 |
| Lee, KP | 1 |
| Park, S | 1 |
| Kim, YW | 1 |
| Menne, S | 1 |
| Yeh, ML | 1 |
| Liang, PC | 1 |
| Trinh, S | 1 |
| Huang, CI | 1 |
| Huang, CF | 1 |
| Hsieh, MY | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chuang, WL | 2 |
| Nguyen, MH | 1 |
| Yu, ML | 1 |
| Chon, HY | 1 |
| Ahn, SH | 3 |
| Kim, YJ | 2 |
| Yoon, JH | 1 |
| Lee, JH | 1 |
| Sinn, DH | 1 |
| Kim, SU | 2 |
| De Clercq, E | 3 |
| Geragotellis, A | 1 |
| Patel, S | 1 |
| Sonderup, M | 1 |
| Wearne, N | 1 |
| Barday, Z | 1 |
| Sanglay, L | 1 |
| Naicker, V | 1 |
| Spearman, CW | 1 |
| Kishimoto, M | 1 |
| Komine, M | 1 |
| Kamiya, K | 1 |
| Sugai, J | 1 |
| Kuwahara, A | 1 |
| Morimoto, N | 1 |
| Ohtsuki, M | 1 |
| Pan, CQ | 2 |
| Afdhal, NH | 1 |
| Ankoma-Sey, V | 1 |
| Bae, H | 2 |
| Curry, MP | 1 |
| Dieterich, D | 1 |
| Frazier, L | 1 |
| Frick, A | 1 |
| Hann, HW | 1 |
| Kim, WR | 1 |
| Kwo, P | 1 |
| Milligan, S | 1 |
| Tong, MJ | 1 |
| Reddy, KR | 1 |
| Kayes, T | 1 |
| Crane, H | 1 |
| Symonds, A | 1 |
| Dumond, J | 1 |
| Cottrell, M | 1 |
| Di Girolamo, J | 1 |
| Manandhar, S | 1 |
| Lim, TH | 1 |
| Gane, E | 2 |
| Kashuba, A | 2 |
| Levy, MT | 2 |
| Kumar, M | 1 |
| Jung, CY | 1 |
| Kim, HW | 1 |
| Lee, JI | 1 |
| Lee, HW | 1 |
| Kim, BS | 1 |
| Suda, G | 1 |
| Baba, M | 1 |
| Yamamoto, Y | 1 |
| Sho, T | 1 |
| Ogawa, K | 1 |
| Kimura, M | 1 |
| Hosoda, S | 1 |
| Yoshida, S | 1 |
| Kubo, A | 1 |
| Fu, Q | 1 |
| Yang, Z | 1 |
| Tokuchi, Y | 1 |
| Kitagataya, T | 1 |
| Maehara, O | 1 |
| Ohnishi, S | 1 |
| Yamada, R | 1 |
| Ohara, M | 1 |
| Kawagishi, N | 1 |
| Natsuizaka, M | 1 |
| Nakai, M | 1 |
| Morikawa, K | 1 |
| Furuya, K | 1 |
| Suzuki, K | 1 |
| Izumi, T | 1 |
| Meguro, T | 1 |
| Terashita, K | 1 |
| Ito, J | 1 |
| Kobayashi, T | 1 |
| Tsunematsu, I | 1 |
| Sakamoto, N | 1 |
| Cheng, CH | 1 |
| Hung, HC | 1 |
| Lee, JC | 1 |
| Wang, YC | 1 |
| Wu, TH | 1 |
| Lee, CF | 1 |
| Wu, TJ | 1 |
| Chou, HS | 1 |
| Chan, KM | 1 |
| Lee, WC | 1 |
| Hwang, EG | 1 |
| Jung, EA | 1 |
| Yoo, JJ | 1 |
| Kim, SG | 1 |
| Kim, YS | 1 |
| Liu, Z | 1 |
| Zhao, Z | 1 |
| Ma, X | 1 |
| Liu, S | 1 |
| Xin, Y | 1 |
| Li, G | 1 |
| Surial, B | 1 |
| Béguelin, C | 1 |
| Chave, JP | 1 |
| Stöckle, M | 1 |
| Boillat-Blanco, N | 1 |
| Doco-Lecompte, T | 1 |
| Bernasconi, E | 1 |
| Fehr, J | 1 |
| Günthard, HF | 1 |
| Schmid, P | 1 |
| Walti, LN | 1 |
| Furrer, H | 1 |
| Rauch, A | 1 |
| Wandeler, G | 1 |
| Zeng, QL | 1 |
| Yu, ZJ | 1 |
| Ji, F | 1 |
| Li, GM | 1 |
| Zhang, GF | 1 |
| Xu, JH | 1 |
| Chen, ZM | 1 |
| Cui, GL | 1 |
| Li, W | 1 |
| Zhang, DW | 1 |
| Li, J | 1 |
| Lv, J | 1 |
| Li, ZQ | 1 |
| Liang, HX | 1 |
| Sun, CY | 1 |
| Pan, YJ | 1 |
| Liu, YM | 1 |
| Wang, FS | 1 |
| Byun, KS | 1 |
| Choi, J | 1 |
| Kim, JH | 1 |
| Lee, YS | 1 |
| Lee, HC | 1 |
| Yoo, BC | 1 |
| Kwon, SY | 1 |
| Gwak, GY | 1 |
| Lim, YS | 2 |
| Chan, L | 1 |
| Asriel, B | 1 |
| Eaton, EF | 1 |
| Wyatt, CM | 1 |
| Agarwal, K | 1 |
| Brunetto, M | 1 |
| Seto, WK | 1 |
| Fung, S | 1 |
| Marcellin, P | 1 |
| Izumi, N | 1 |
| Sharma, M | 1 |
| Janssen, HLA | 1 |
| Çelen, MK | 1 |
| Furusyo, N | 1 |
| Shalimar, D | 1 |
| Yoon, KT | 1 |
| Trinh, H | 1 |
| Flaherty, JF | 1 |
| Gaggar, A | 1 |
| Lau, AH | 1 |
| Cathcart, AL | 1 |
| Lin, L | 1 |
| Bhardwaj, N | 1 |
| Suri, V | 1 |
| Mani Subramanian, G | 1 |
| Gane, EJ | 1 |
| Buti, M | 1 |
| Chan, HLY | 1 |
| Alsunaid, SR | 1 |
| Ashraf, H | 1 |
| Soubani, AO | 1 |
| Gallant, J | 1 |
| Brunetta, J | 1 |
| Crofoot, G | 1 |
| Benson, P | 1 |
| Mills, A | 1 |
| Brinson, C | 1 |
| Oka, S | 1 |
| Cheng, A | 1 |
| Garner, W | 1 |
| Fordyce, M | 1 |
| Das, M | 1 |
| McCallister, S | 1 |
| Liu, Y | 1 |
| Miller, MD | 1 |
| Kitrinos, KM | 1 |
| Sureau, C | 1 |
| Salisse, J | 1 |
| Turner, GC | 1 |
| Field, AM | 1 |
| Lasheen, RM | 1 |
| Tood, RM | 1 |
| White, GB | 1 |
| Porter, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist[NCT04594356] | 120 participants (Actual) | Observational | 2020-11-19 | Completed | |||
| Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection[NCT04326036] | Early Phase 1 | 10 participants (Anticipated) | Interventional | 2020-03-25 | Enrolling by invitation | ||
| Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction[NCT03115736] | Phase 2 | 24 participants (Actual) | Interventional | 2017-05-23 | Completed | ||
| Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir[NCT03241641] | Phase 4 | 174 participants (Actual) | Interventional | 2017-10-26 | Completed | ||
| Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study[NCT04939441] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-20 | Active, not recruiting | ||
| Efficacy and Safety of Tenofovir Alafenamide in Chronic Hepatitis B Patients With Suboptimal Response Following Nucleos(t)Ide Therapy[NCT04201808] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B[NCT05937178] | 20,000 participants (Anticipated) | Observational | 2023-01-31 | Recruiting | |||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B[NCT01940341] | Phase 3 | 426 participants (Actual) | Interventional | 2013-09-12 | Completed | ||
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B[NCT01940471] | Phase 3 | 875 participants (Actual) | Interventional | 2013-09-11 | Completed | ||
| Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.01 |
| TDF 300 mg | 0.02 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.288 |
| TDF 300 mg | -2.156 |
(NCT01940341)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.876 |
| TDF 300 mg | -2.514 |
The primary efficacy endpoint was determined by the achievement of HBV DNA < 29 IU/mL at Week 48. (NCT01940341)
Timeframe: Week 48
| Intervention | Percentage of participants (Number) |
|---|---|
| TAF 25 mg | 94.0 |
| TDF 300 mg | 92.9 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940341)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 18.1 | 1.1 | 0 |
| TDF 300 mg | 16.4 | 2.1 | 0 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | mg/dL (Mean) |
|---|---|
| TAF 25 mg | 0.009 |
| TDF 300 mg | 0.026 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.100 |
| TDF 300 mg | -1.715 |
(NCT01940471)
Timeframe: Baseline, Week 48
| Intervention | percentage change (Mean) |
|---|---|
| TAF 25 mg | -0.417 |
| TDF 300 mg | -2.294 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 10.3 |
| TDF 300 mg | 8.1 |
(NCT01940471)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| TAF 25 mg | 63.9 |
| TDF 300 mg | 66.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. (NCT01940471)
Timeframe: Up to 48 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| TAF 25 mg | 23.9 | 3.5 | 0 |
| TDF 300 mg | 17.8 | 4.5 | 0.3 |
6 reviews available for alanine and Hepatitis B
| Article | Year |
|---|---|
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Dr | 2021 |
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis.
Topics: Adenine; Alanine; Cholesterol; Cholesterol, LDL; Dyslipidemias; Hepatitis B; Hepatitis B, Chronic; H | 2023 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, | 2023 |
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; | 2018 |
Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Drug Interactions; Glomerular Filtration Rate; Hep | 2018 |
Tenofovir alafenamide (Vemlidy) for hepatitis B.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Clinical Trials as Topic; Hepatitis B; Humans; Tenofovi | 2017 |
3 trials available for alanine and Hepatitis B
| Article | Year |
|---|---|
Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Tenofovir; Treatment Outcome | 2022 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Alanine Transaminase; Bone Density; DN | 2018 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Em | 2016 |
19 other studies available for alanine and Hepatitis B
| Article | Year |
|---|---|
Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks.
Topics: Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Disease Models, Animal; Drug | 2021 |
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide
Topics: Adenine; Alanine; Body Weight; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Male; Middle Aged; | 2022 |
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients.
Topics: Aged; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B; Hepatitis B, Chron | 2021 |
Tenofovir alafenamide: An initial experience at Groote Schuur Hospital, Cape Town, South Africa.
Topics: Adult; Alanine; Antiviral Agents; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis B | 2022 |
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepat | 2022 |
First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Topics: Alanine; Antiviral Agents; Hepatitis B; Hepatitis B, Chronic; Humans; Prospective Studies; Retrospec | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Female; Hepatitis B; Hepatitis B, Chronic; HIV Infections; | 2022 |
Tenofovir Alafenamide use in pregnant women with chronic hepatitis B virus infection: more data needed.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Hu | 2022 |
Plasma and breast milk pharmacokinetics of tenofovir alafenamide of mothers with chronic hepatitis B infection-Authors' reply.
Topics: Adenine; Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Milk, Human; | 2022 |
Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Guanine; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Long | 2022 |
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis B virus; Hepatitis B, Chroni | 2023 |
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation.
Topics: Adenine; Alanine; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Topics: Adenine; Aged; Alanine; Anti-HIV Agents; Female; Glomerular Filtration Rate; Hepatitis B; Hepatitis | 2020 |
Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
Topics: Alanine; Antiviral Agents; Female; Hepatitis B; Hepatitis B, Chronic; Humans; Infant; Infant, Newbor | 2021 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T | 2018 |
Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro.
Topics: Adenine; Alanine; Antiviral Agents; Drug Resistance, Viral; Genotype; Hep G2 Cells; Hepatitis B; Hep | 2017 |
A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant.
Topics: Alanine; Amino Acid Substitution; Binding Sites; Detergents; Heparitin Sulfate; Hepatitis B; Hepatit | 2013 |
SH (Australia) antigen in early life.
Topics: Adult; Agglutination; Alanine; Alanine Transaminase; Antibodies; Bilirubin; Blood Protein Electropho | 1971 |